公开(公告)号：US10059734B2

公开(公告)日：2018-08-28

申请号：US15581834

申请日：2017-04-28

Applicant: FUJIFILM Corporation

Inventor： Hidenobu Kuniyoshi ,  Daisuke Nakagawa ,  Takuya Matsumoto ,  Yuji Yoshimitsu

IPC: C07H19/10 ,  A61P35/02 ,  A61K31/7068 ,  A61P35/00

CPC classification number: C07H19/10 ,  A61K31/7068 ,  A61P35/00 ,  A61P35/02

Abstract: Disclosed are a compound and a pharmaceutical composition that exhibit an excellent drug efficacy against a tumor, in particular a tumor which has acquired resistance to gemcitabine. Specifically, provided is a thionucleoside derivative represented by General Formula [1] (in the formula, R1 represents a hydroxyl group which may be protected, a C1-20 alkoxy group which may be substituted, or the like; R2 represents a C1-20 alkoxy group which may be substituted, a C3-8 cycloalkoxy group which may be substituted, or the like; and R3 represents a hydrogen atom or the like); or a salt thereof. Further, provided is a pharmaceutical composition containing such a thionucleoside derivative or a salt thereof.

公开(公告)号：US11319347B2

公开(公告)日：2022-05-03

申请号：US16577517

申请日：2019-09-20

Applicant: FUJIFILM Corporation

Inventor： Masaaki Inoue ,  Takashi Tamura ,  Yuji Yoshimitsu ,  Takahiro Hohsaka ,  Takayoshi Watanabe

IPC: C07K7/64

Abstract: An object of the present invention is to provide a novel cyclic peptide compound excellent in cell membrane permeability, a method for producing the same, a composition for screening use, and a method for selecting a cyclic peptide compound that binds to a target substance. According to the present invention, a peptide compound represented by Formula (1) or a salt thereof is provided. In the formula, the symbols have the meanings as defined in the specification of the present application.

公开(公告)号：US20240173437A1

公开(公告)日：2024-05-30

申请号：US18411057

申请日：2024-01-12

Applicant: FUJIFILM Corporation

Inventor： Kenji SHIROKANE ,  Yuji Yoshimitsu ,  Naoka Hamada ,  Yoshinori Kanazawa ,  Hiroaki Tanaka

IPC: A61K49/00 ,  A61K47/54 ,  A61K47/65 ,  A61K47/68 ,  A61K51/10 ,  G01N33/58

CPC classification number: A61K49/0015 ,  A61K47/545 ,  A61K47/548 ,  A61K47/65 ,  A61K47/6873 ,  A61K51/1096 ,  G01N33/582

Abstract: There are provided a compound having two or more phosphor moieties of which light absorption characteristics are equivalent to each other, in which the phosphor moieties adjacent to each other are each linked through a group including a structure represented by General Formula (I), and a labeled biological substance using the compound.






In the formula, X1 to X3 represent —O—, —S—, >NR1, or >CR2R3.
R1 to R3 represent a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, an aryl group, a heteroaryl group, an acyl group, —NR8R9, —OR10, or an anionic group.
R1 to R10 represent a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, an acyl group, an aryl group, a heteroaryl group, or an anionic group.
n is an integer of 2 or more.
* represents a bonding site.

公开(公告)号：US10385089B2

公开(公告)日：2019-08-20

申请号：US16037375

申请日：2018-07-17

Applicant: FUJIFILM Corporation

Inventor： Hidenobu Kuniyoshi ,  Daisuke Nakagawa ,  Takuya Matsumoto ,  Yuji Yoshimitsu

IPC: C07H19/10 ,  A61P35/02 ,  A61K31/7068 ,  A61P35/00

Abstract: Disclosed are a compound and a pharmaceutical composition that exhibit an excellent drug efficacy against a tumor, in particular a tumor which has acquired resistance to gemcitabine. Specifically, provided is a thionucleoside derivative represented by General (in the formula, R1 represents a hydroxyl group which may be protected, a C1-20 alkoxy group which may be substituted, or the like; R2 represents a C1-20 alkoxy group which may be substituted, a C3-8 cycloalkoxy group which may be substituted, or the like; and R3 represents a hydrogen atom or the like); or a salt thereof. Further, provided is a pharmaceutical composition containing such a thionucleoside derivative or a salt thereof.